Selected articles
Articles for label Kocák Ivo are displayed.. Show all articles
Concomitant administration of nivolumab and targeted radiotherapy with a significant clinical effect on metastatic melanoma in an elderly patient – ca
06/2020 MUDr. Ivo Kocák, Ph.D.; doc. MUDr. Ilona Kocáková, Ph.D.; doc. MUDr. Zdeněk Řehák, Ph.D.
The following case report describes a comprehensive diagnostic and therapeutic procedure in an elderly patient with generalized melanoma.
ENTIRE ARTICLE
The following case report describes a comprehensive diagnostic and therapeutic procedure in an elderly patient with generalized melanoma.
The sequence of docetaxel‐cabazitaxel‐enzalutamid in men with metastatic castration‐resistant prostate cancer
02/2018 MUDr. Ivo Kocák, Ph.D., MUDr. Zdenek Řehák, Ph.D.
In the present case, we present a possible sequential treatment for metastatic castration-resistant prostate cancer into the skeleton (mCRPC). Because of symptomatic disease, chemotherapy therapy has been launched that has been able to effectively reduce the symptoms of the disease. The tolerance of the docetaxel-cabazitaxel sequence was very good. Once the chemotherapy options have been exhausted, ARTA treatment with enzalutamide has been chosen, which further effectively stabilizes the disease, maintains overall good status. Sequential treatment of mCRPC has lasted nearly 4 years.
ENTIRE ARTICLE
In the present case, we present a possible sequential treatment for metastatic castration-resistant prostate cancer into the skeleton (mCRPC). Because of symptomatic disease, chemotherapy therapy has been launched that has been able to effectively reduce the symptoms of the disease. The tolerance of the docetaxel-cabazitaxel sequence was very good. Once the chemotherapy options have been exhausted, ARTA treatment with enzalutamide has been chosen, which further effectively stabilizes the disease, maintains overall good status. Sequential treatment of mCRPC has lasted nearly 4 years.